Fibrinogen Milano XII: a dysfunctional variant containing 2 amino acid substitutions, Aalpha R16C and gamma G165R.
Fibrinogen Milano XII was detected in an asymptomatic Italian woman, whose routine coagulation test results revealed a prolonged thrombin time. Fibrinogen levels in functional assays were considerably lower than levels in immunologic assays. Polymerization of purified fibrinogen was strongly impaired in the presence of calcium or ethylenediaminetetraacetic acid (EDTA). Two heterozygous structural defects were detected by DNA analysis: Aalpha R16C and gamma G165R. As seen previously with other heterozygous Aalpha R16C variants, thrombin-catalyzed release of fibrinopeptide A was 50% of normal. Additionally, the release of fibrinopeptide B was delayed. Immunoblotting analysis with antibodies to human serum albumin indicated that albumin is bound to Aalpha 16 C. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of plasmin digests of fibrinogen Milano XII in the presence of calcium or EDTA showed both normal and novel D1 and D3 fragments. Further digestion of abnormal D3 fragments by chymotrypsin resulted in degradation products of the same size as the fragments derived from normal fibrinogen. SDS-PAGE analysis under reducing conditions showed no difference between normal fibrinogen and fibrinogen Milano XII or between their plasmic fragments. Circular dichroism analysis revealed a shift in the mean residual ellipticity and a significant reduction of the alpha-helix content in the variant D3 fragment. It is concluded that the Aalpha-chain substitution is mainly responsible for the coagulation abnormalities, whereas the substitution in the gamma-chain induced a conformational change in the D3 fragment.
Bolliger-Stucki
B
B
Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland. bettina_bollinger@med.unc.edu
Lord
S T
ST
Furlan
M
M
D000368:Aged; D001778:Blood Coagulation Disorders / Q000235:genetics; D002118:Calcium / Q000494:pharmacology; D002918:Chymotrypsin / Q000378:metabolism; D002942:Circular Dichroism; D004247:DNA / Q000032:analysis; D004492:Edetic Acid / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D015241:Fibrinogens, Abnormal / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D005344:Fibrinopeptide A / Q000378:metabolism; D005345:Fibrinopeptide B / Q000378:metabolism; D006579:Heterozygote; D006801:Humans; D015151:Immunoblotting; D007700:Kinetics; D009154:Mutation; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism; D011487:Protein Conformation; D017422:Sequence Analysis, DNA; D012709:Serum Albumin / Q000378:metabolism; D013917:Thrombin / Q000378:metabolism; D013918:Thrombin Time
D015241:Fibrinogens, Abnormal; D010446:Peptide Fragments; D012709:Serum Albumin; D005344:Fibrinopeptide A; D005345:Fibrinopeptide B; D005340:Fibrinogen; D004247:DNA; D004492:Edetic Acid; D002918:Chymotrypsin; D013917:Thrombin; D005341:Fibrinolysin; D002118:Calcium